FDA warned Fei Fah Medical Manufacturing over inadequate stability data, unvalidated test methods, and supplier testing failures for over-the-counter drugs.
What happened
FDA reviewed records Fei Fah submitted after FDA's May 18, 2021 request for records and the firm's March 28, 2022 response. FDA found inadequate stability data to support expiration dates, unvalidated assay methods and missing impurity specifications, and failure to test incoming components or qualify suppliers. The letter also notes similar stability findings in March 2013 and December 2015 inspections.
What FDA found
The firm lacked adequate stability data to support expiration dates and did not use methods that can detect impurities or degradants.
21 CFR 211.166(a)The firm did not establish suitable laboratory controls, validate its assay test method, or set release specifications for impurities.
21 CFR 211.160(b)The firm did not test each incoming component lot for identity and did not qualify suppliers or verify their certificates of analysis.
21 CFR 211.84(d)(1) and 211.84(d)(2)
What FDA wants
FDA tells the firm to correct the violations promptly and respond in writing within 15 working days with corrective action plans, independent assessments, test results, and any reason for delay.
Who should pay attention
- brands that buy OTC drugs from this contract manufacturer
- U.S. distributors and retailers selling its drug products
- companies relying on supplier certificates of analysis for incoming components
This is a summary. Read the original letter on fda.gov.